Clinical Trial Update: QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating QL1706-based therapy in advanced endometrial cancer patients who progressed after PD-1/PD-L1 therapy; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Cancer

Drugs mentioned

• QL1706

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Endometrial Adenocarcinoma, Endometrial Cancer | Phase 2 | Status: RECRUITING